Under optimized reaction conditions, by directly using the hemostatic drugs 4-aminomethylbenzoic acid (ABA) and tranexamic acid (TA) as separate comonomers of lactic acid (LA), a series of copolymers, P(LA- co -ABA) and P(LA- co -TA), respectively, with different molar feed ratios were designed and synthesized via melt polycondensation and used as biobased polymeric sustained-release hemostatic materials. Their structure, properties and morphology were systematically investigated by Fourier transform infrared spectrometer (FTIR), proton nuclear magnetic resonance ( 1 H NMR), gel permeation chromatography (GPC), X-ray diffraction (XRD), differential scanning calorimetery (DSC), thermogravimetric (TG), scanning electron microscopy (SEM), water contact angle and degradation tests. The degradation rate within 7 weeks can reach 77%. When the molar feed ratios of ABA and TA are 20% and 10%, respectively, the corresponding copolymers have relatively lower crystallinity and smaller water contact angle and exhibit the best coagulation performance. In addition, these powdery copolymers have good application convenience, can form a degradable protective membrane similar to a blood scab on the wound surface and continuously exert hemostatic effects to promote wound healing, as anticipated. A series of polymeric hemostatic materials are prepared in one-step, by using biobased lactic acid monomers and mature hemostatic drugs (4-aminomethylbenzoic acid or tranexamic acid) through direct melt polycondensation. These materials are powdery with rough and irregular surfaces, and the powder particle size is ~8–30 μm, which is beneficial to the application, immediate hemostasis and scab-bionic membrane forming. Moreover, after the degradation of these materials at 37 °C, more monomers will be released, resulting in a higher efficiency and long-term hemostatic function.

中文翻译：

---

生物基痂皮仿生止血聚合物的高效合成、表征和应用

在优化的反应条件下，通过直接使用止血药物4-氨基甲基苯甲酸（ABA）和氨甲环酸（TA）作为乳酸（LA）的单独共聚单体，一系列共聚物，P（LA-co-ABA）和P（ LA-co-TA)，分别具有不同的摩尔进料比，通过熔融缩聚被设计和合成，并用作生物基聚合物缓释止血材料。通过傅里叶变换红外光谱（FTIR）、质子核磁共振（ 1 H NMR）、凝胶渗透色谱（GPC）、X射线衍射（XRD）、差示扫描量热（DSC）、热重 (TG)、扫描电子显微镜 (SEM)、水接触角和降解测试。7周内降解率可达77%。当ABA和TA的摩尔投料比分别为20%和10%时，相应共聚物的结晶度较低，水接触角较小，混凝性能最好。此外，这些粉末状共聚物具有良好的应用便利性，可以在创面形成类似于血痂的可降解保护膜，并持续发挥止血作用，促进创面愈合，正如预期的那样。采用生物基乳酸单体和成熟的止血药物（4-氨基甲基苯甲酸或氨甲环酸），通过直接熔融缩聚，一步法制备一系列高分子止血材料。这些材料呈粉状，表面粗糙不规则，粉末粒径~8-30 μm，有利于应用，立即止血和结痂仿生膜形成。此外，这些材料在 37°C 降解后，会释放更多的单体，从而具有更高的效率和长期止血功能。